Skip Navigation
Skip to contents

Ann Coloproctol : Annals of Coloproctology

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Dose"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Efficacy of Dose-Escalated Radiotherapy for Recurrent Colorectal Cancer
Sunmi Jo, Yunseon Choi, Sung-Kwang Park, Jin-Young Kim, Hyun Jung Kim, Yun-Han Lee, Won Yong Oh, Heunglae Cho, Ki Jung Ahn
Ann Coloproctol. 2016;32(2):66-72.   Published online April 30, 2016
DOI: https://doi.org/10.3393/ac.2016.32.2.66
  • 4,053 View
  • 36 Download
  • 8 Web of Science
  • 7 Citations
AbstractAbstract PDF
Purpose

This study aimed to evaluate the effects of radiotherapy (RT) on progression-free survival (PFS) for patients with recurrent colorectal cancer.

Methods

We reviewed the records of 22 patients with recurrent colorectal cancer treated with RT between 2008 and 2014. The median radiation dose for recurrent disease was 57.6 Gy (range, 45–75.6 Gy). Patients were divided into 2 groups according to the type of RT: patients underwent RT without previous history of irradiation (n = 14) and those treated with secondary RT (reirradiation: n = 8) at the time of recurrence.

Results

The median follow-up period was 24.9 months (range, 4.5–66.6 months). Progression was observed in 14 patients (including 8 with loco-regional failure and 9 with distant metastases). Distant metastases were related to the RT dose (<70 Gy, P = 0.031). The 2-year loco-regional control (LRC), PFS, and overall survival (OS) rates were 74.6%, 45.1%, and 82.0%, respectively. The LRC rate was not different between the patients treated with RT for the first time and those treated with reirradiation (P = 0.101, 2-year LRC 79.5% vs. 41.7%). However, reirradiation was related to poor PFS (P = 0.022) and OS (P = 0.002). An escalated RT dose (≥70 Gy) was associated with a higher PFS (P = 0.014, 2-year PFS 63.5% vs. 20.8%).

Conclusion

Salvage RT for locally recurrent colorectal cancer can be offered when surgery is impossible. Dose-escalated RT shows a possible benefit in reducing the risk of progression.

Citations

Citations to this article as recorded by  
  • Carbon-ion Radiotherapy for Colorectal Cancer
    Shigeru Yamada, Hirotoshi Takiyama, Yuka Isozaki, Makoto Shinoto, Hirokazu Makishima, Naoyoshi Yamamoto, Hiroshi Tsuji
    Journal of the Anus, Rectum and Colon.2021; 5(2): 113.     CrossRef
  • LncRNA TTN‐AS1/miR‐134‐5p/PAK3 axis regulates the radiosensitivity of human large intestine cancer cells through the P21 pathway and AKT/GSK‐3β/β‐catenin pathway
    Zhenkui Zuo, Shuling Ji, Lulu He, Yage Zhang, Zining Peng, Jiarui Han
    Cell Biology International.2020; 44(11): 2284.     CrossRef
  • A Review on the Special Radiotherapy Techniques of Colorectal Cancer
    Shing Yau Tam, Vincent W. C. Wu
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Comparison of overall survival and quality of life between patients undergoing anal reconstruction and patients undergoing traditional lower abdominal stoma after radical resection
    P. Du, S.-Y. Wang, P.-F. Zheng, J. Mao, H. Hu, Z.-B. Cheng
    Clinical and Translational Oncology.2019; 21(10): 1390.     CrossRef
  • Prospective Observational Study of High-Dose Carbon-Ion Radiotherapy for Pelvic Recurrence of Rectal Cancer (GUNMA 0801)
    Shintaro Shiba, Masahiko Okamoto, Hiroki Kiyohara, Tatsuya Ohno, Takuya Kaminuma, Takayuki Asao, Hitoshi Ojima, Ken Shirabe, Hiroyuki Kuwano, Takashi Nakano
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Effects of varying radiation dosages on MMP1 expression, and MMP1 knockdown on the viability and migration of SW620 cells
    Fang Ju, Na Li, Wenming Wang, Haicheng Yuan
    Molecular Medicine Reports.2019;[Epub]     CrossRef
  • Dose-Escalated Radiotherapy for the Treatment of Patients With Recurrent Colorectal Cancer
    Hyung Jin Kim, Seong Taek Oh
    Annals of Coloproctology.2016; 32(2): 47.     CrossRef
Oncologic Outcome after Cessation or Dose Reduction of Capecitabine in Patients with Colon Cancer
Jung-A Yun, Hee Cheol Kim, Hyun-Sook Son, Hyoung Ran Kim, Hae Ran Yun, Yong Beom Cho, Seong Hyeon Yun, Woo Yong Lee, Ho-Kyung Chun
J Korean Soc Coloproctol. 2010;26(4):287-292.   Published online August 31, 2010
DOI: https://doi.org/10.3393/jksc.2010.26.4.287
  • 3,479 View
  • 38 Download
  • 6 Citations
AbstractAbstract PDF
Purpose

Oral capecitabine has been used as adjuvant therapy for colorectal cancer patients since the 1990s. Patient-initiated cessation or reduced use of capecitabine occurs widely for various reasons, yet the consequences of these actions are unclear. The present study sought to clarify treatment outcomes in such patients.

Methods

The study included 173 patients who had been diagnosed with stage II or III colon cancer according to the pathologic report after radical surgery at Samsung Medical Center from May 2005 to June 2007 and who had received capecitabine as adjuvant therapy. The patients were divided into groups according to whether the dose was reduced (I, dose maintenance; II, dose reduction) or stopped (A, cycle completion; B, cycle cessation). Recurrence and disease-free survival rates between the two groups each were analyzed.

Results

Of the 173 patients, 128 (74.6%) experienced complications, most frequently hand-foot syndrome (n = 114). Reduction (n = 35) or cessation (n = 18) of medication was most commonly due to complications. Concerning reduced dosage, both groups displayed no statistically significant differences in recurrence rate and 3-year disease-free survival rate. Concerning discontinued medication use, the cycle completion group showed an improved recurrence rate (P = 0.048) and 3-year disease-free survival rate (P = 0.028).

Conclusion

The results demonstrate that maintaining compliance with capecitabine as an adjuvant treatment for colon cancer to preventing complications positively affects patient prognosis.

Citations

Citations to this article as recorded by  
  • Medication Perceptions Mediate the Association between Illness Perceptions and Adherence to Oral Anticancer Agents among Patients with Gastrointestinal Tract Cancer: A Cross-sectional Study
    Yongfeng Chen, Marques Shek Nam Ng, Xulian Wei, LiYuan Zhang, Kai Chow Choi, Yan Ma, Fang Wang, Carmen Wing Han Chan
    European Journal of Oncology Nursing.2024; : 102720.     CrossRef
  • The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients
    Doreen Z. Mhandire, Andrew K. L. Goey
    Molecular Diagnosis & Therapy.2022; 26(2): 137.     CrossRef
  • Global Cancer Burden and Natural Disasters: A Focus on Asia’s Vulnerability, Resilience Building, and Impact on Cancer Care
    Roselle De Guzman, Monica Malik
    Journal of Global Oncology.2019; (5): 1.     CrossRef
  • Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer
    Devon J. Boyne, Colleen A. Cuthbert, Dylan E. O’Sullivan, Tolulope T. Sajobi, Robert J. Hilsden, Christine M. Friedenreich, Winson Y. Cheung, Darren R. Brenner
    JAMA Network Open.2019; 2(5): e194154.     CrossRef
  • 5-fluorouracil Toxicity Mechanism Determination in Human Keratinocytes: in vitro Study on HaCaT Cell Line
    Jan Hartinger, Pavel Veselý, Martin Šíma, Irena Netíková, Eva Matoušková, Luboš Petruželka
    Prague Medical Report.2017; 118(4): 128.     CrossRef
  • An exploratory study to identify risk factors for the development of capecitabine‐induced Palmar Plantar Erythrodysesthesia (PPE)
    Annie Law, Sue Dyson, Denis Anthony
    Journal of Advanced Nursing.2015; 71(8): 1825.     CrossRef
  • FirstFirst
  • PrevPrev
  • Page of 1
  • Next Next
  • Last Last

Ann Coloproctol : Annals of Coloproctology Twitter Facebook
TOP